Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669273 | 1.00 | SCN9A (0.46) | SCN9ASOS1MAPTTP53KDM4E | |
| SCHEMBL16109346 | 0.92 | SCN9A (0.48) | SCN9AMAPTTP53KDM4EMEN1 | |
| SCHEMBL19627592 | 0.91 | SCN9A (0.43) | SCN9ASOS1MAPTTP53MEN1 | |
| SCHEMBL1109044 | 0.90 | SCN9A (0.47) | SCN9AMAPTTP53KDM4EMEN1 | |
| SCHEMBL19631763 | 0.89 | SCN9A (0.46) | SCN9AMAPTTP53MEN1KMT2A | |
| SCHEMBL325911 | 0.89 | SCN9A (0.46) | SCN9AMAPTTP53KDM4EMEN1 | |
| SCHEMBL20449150 | 0.89 | SCN9A (0.46) | SCN9AMAPTTP53KDM4EMEN1 | |
| SCHEMBL20449236 | 0.88 | SCN9A (0.46) | SCN9AMAPTTP53KDM4EMEN1 | |
| SCHEMBL29736437 | 0.88 | SCN9A (0.40) | SCN9AMAPTTP53KDM4EMEN1 | |
| SCHEMBL1093593 | 0.88 | SCN9A (0.40) | SCN9AMAPTTP53KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20220000844-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2022-01-06 | — | — | US | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| CN-109526219-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | disclosed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SOS1 427/4885MAPT 11/4885 |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPM6, SCN1A | SCN9A 32/4885SOS1 164/4885MAPT 1270/4885 |
| US-20220000844-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | TRPV1, SCN7A, SCN1A | SCN9A 14/4885SOS1 383/4885MAPT 2601/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | SCN9A 75/4885SOS1 365/4885MAPT 138/4885 |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | SCN9A 46/4885SOS1 455/4885MAPT 144/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | SCN9A 52/4885SOS1 411/4885MAPT 145/4885 |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | SCN9A 52/4885SOS1 411/4885MAPT 145/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SOS1 427/4885MAPT 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.